173 related articles for article (PubMed ID: 31505222)
1. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
[TBL] [Abstract][Full Text] [Related]
2. Design of a Novel PEGylated Liposomal Vector for Systemic Delivery of siRNA to Solid Tumors.
Song F; Sakurai N; Okamoto A; Koide H; Oku N; Dewa T; Asai T
Biol Pharm Bull; 2019; 42(6):996-1003. PubMed ID: 31155597
[TBL] [Abstract][Full Text] [Related]
3. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
4. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
Li Y; Cheng Q; Jiang Q; Huang Y; Liu H; Zhao Y; Cao W; Ma G; Dai F; Liang X; Liang Z; Zhang X
J Control Release; 2014 Feb; 176():104-14. PubMed ID: 24365128
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
Mehta A; Dalle Vedove E; Isert L; Merkel OM
Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
[TBL] [Abstract][Full Text] [Related]
6. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.
Chen CW; Lu DW; Yeh MK; Shiau CY; Chiang CH
Int J Nanomedicine; 2011; 6():2567-80. PubMed ID: 22128247
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.
Lo JH; Kwon EJ; Zhang AQ; Singhal P; Bhatia SN
Bioconjug Chem; 2016 Oct; 27(10):2323-2331. PubMed ID: 27583545
[TBL] [Abstract][Full Text] [Related]
8. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
9. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
10. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
11. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells.
Uemura Y; Naoi T; Kanai Y; Kobayashi K
Pharm Dev Technol; 2019 Mar; 24(3):263-268. PubMed ID: 29688101
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
13. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
14. PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo.
Aldrian G; Vaissière A; Konate K; Seisel Q; Vivès E; Fernandez F; Viguier V; Genevois C; Couillaud F; Démèné H; Aggad D; Covinhes A; Barrère-Lemaire S; Deshayes S; Boisguerin P
J Control Release; 2017 Jun; 256():79-91. PubMed ID: 28411182
[TBL] [Abstract][Full Text] [Related]
15. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
16. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
17. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
18. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression.
Dar GH; Gopal V; Rao NM
Mol Pharm; 2015 Feb; 12(2):610-20. PubMed ID: 25545110
[TBL] [Abstract][Full Text] [Related]
20. Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery
Zhu X; Tao W; Liu D; Wu J; Guo Z; Ji X; Bharwani Z; Zhao L; Zhao X; Farokhzad OC; Shi J
Theranostics; 2017; 7(7):1990-2002. PubMed ID: 28638484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
